A recent real-world study conducted by Stallergenes Greer has provided groundbreaking evidence of the effectiveness of Stallergenes Greer sublingual allergen immunotherapy (SLIT-liquid) in preventing and treating asthma in patients with allergic rhinitis. The study, known as EfficAPSI, is the largest of its kind to date, with over 440,000 patients followed over a span of nine years.
The results of the study, published in the Lancet Regional Health-Europe, revealed that treatment with Stallergenes Greer SLIT-liquid was associated with a 36% reduction in the risk of new asthma events in the overall cohort of patients. Furthermore, it showed a 38% reduction in the risk of asthma onset in patients without pre-existing asthma. For patients with pre-existing asthma, SLIT-liquid treatment resulted in a one-third reduction in the need for stepping up asthma medication according to the Global Initiative for Asthma (GINA) guidelines.
“This extensive study confirms the role of SLIT-liquid in reshaping asthma management,” commented Professor Pascal Demoly, Head of the Pulmonology, Allergology and Thoracic Oncology Department at Montpellier University Hospital. “The findings deliver important insights on the relevance of SLIT-liquid as a personalized treatment tailored to each patient’s unique needs.”
The study also demonstrated the broader public health impact of SLIT-liquid treatments by preventing the onset and worsening of asthma. The findings suggest that SLIT-liquid not only provides effective symptom relief but also has disease-modifying properties, making it an important therapeutic option for patients with allergic rhinitis and asthma.
Dr Elena Rizova, Chief Medical Officer of Stallergenes Greer, emphasized the company’s commitment to advancing disease-modifying solutions for allergy treatment. “Through this real-world study, we are dedicated to improving the quality of life for people with allergies and redefining respiratory care,” she stated.
Stallergenes Greer plans to continue using real-world approaches to gather further evidence supporting the benefits of SLIT-liquid. Future studies will focus on additional endpoints to better understand the impact of SLIT-liquid on asthma prevention and treatment.
In conclusion, the EfficAPSI study provides compelling evidence that Stallergenes Greer SLIT-liquid is an effective and personalized treatment option for patients with allergic rhinitis and asthma. These findings have the potential to transform asthma management and improve the lives of millions of individuals affected by these conditions.
In addition to the information presented in the article, it is important to discuss current market trends related to sublingual allergen immunotherapy (SLIT) and the treatment of asthma. SLIT-liquid has gained popularity as a viable alternative to traditional allergy treatments, such as subcutaneous immunotherapy (SCIT), due to its ease of administration and potential for improved patient compliance. SLIT-liquid involves placing drops of allergen extracts under the tongue, allowing for gradual desensitization to specific allergens.
Forecasts in the field of SLIT-liquid indicate a positive outlook for its continued growth and adoption. With increasing awareness and demand for personalized healthcare solutions, SLIT-liquid has the potential to become a widely accepted treatment option for asthma and allergic rhinitis.
One of the key advantages of SLIT-liquid is its ability to provide long-term symptom relief and modify the progression of the disease. This makes it a valuable therapeutic option for patients with allergic rhinitis and asthma, as it not only alleviates symptoms but also addresses the underlying immune response. The EfficAPSI study supports this claim by showing a significant reduction in the risk of new asthma events and the need for escalation of asthma medications.
However, it is important to note some of the challenges and controversies associated with the use of SLIT-liquid. One of the challenges is that SLIT-liquid requires consistent and long-term adherence to treatment to achieve optimal results. Compliance with the prescribed treatment regimen may be a barrier for some patients, as it requires daily administration over an extended period of time.
There may also be concerns regarding the potential for adverse reactions or side effects with SLIT-liquid. While the EfficAPSI study did not mention any significant adverse events, it is important for healthcare providers to closely monitor patients and educate them about potential risks.
Moving forward, further research and studies are needed to better understand the full impact of SLIT-liquid on asthma prevention and treatment. Additionally, ongoing efforts to gather real-world evidence and data will help to strengthen the body of knowledge surrounding SLIT-liquid and its effectiveness.
For more information on Stallergenes Greer and SLIT-liquid, you can visit their official website: link name.